Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05664464 | Glutamate Inhibitors in Glioblastoma(GLUGLIO) | recruiting | Phase 1 / Phase 2 | 120 | University of ZurichOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06002659 | CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)(CARMA-01) | recruiting | Phase 1 / Phase 2 | 18 | Uppsala UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06383728 | Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma(GALAXY-02) | recruiting | Phase 2 | 51 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06406634 | Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06404697 | Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients | recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06251947 | Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06397222 | Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC | recruiting | Phase 2 | 23 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05869279 | Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 29 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT03842943 | Neoadjuvant Combination Immunotherapy for Stage III Melanoma | recruiting | Phase 2 | 28 | University of LouisvilleOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT06395844 | Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06151743 | Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma | recruiting | Phase 2 | 32 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06391190 | Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06389422 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06385990 | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | recruiting | Phase 2 | 53 | Hunan Cancer HospitalOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06387056 | Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)(SEGNO) | recruiting | Phase 2 | 40 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT03685890 | Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion(NivoILP) | recruiting | Phase 1 / Phase 2 | 74 | Vastra Gotaland RegionOTHER_GOV | 2 | Apr 25, 2024 | clinicaltrials |
| NCT03767075 | A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)(BoB) | recruiting | Phase 2 | 1,000 | Vall d'Hebron Institute of OncologyOTHER | 7 | Apr 25, 2024 | clinicaltrials |
| NCT05228431 | Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 121 | Zhen-Hai LuOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | recruiting | Phase 2 | 111 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT05817214 | Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer | recruiting | Phase 2 | 35 | Zhongnan HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04204837 | Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | recruiting | Phase 2 | 61 | Salzburger LandesklinikenOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT03999723 | Combining Active and Passive DNA Hypomethylation(EVI-3) | recruiting | Phase 2 | 196 | Kirsten GrønbækOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | recruiting | Phase 2 | 20 | Lei ZHAOOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363825 | A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 57 | Fujian Medical UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06371586 | Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC | recruiting | Phase 2 | 67 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363734 | Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial | recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04793919 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | recruiting | Phase 2 | 89 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 12 | Apr 15, 2024 | clinicaltrials |
| NCT05905315 | Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC(VULCANIZE-II) | recruiting | Phase 2 | 98 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06149130 | Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer | recruiting | Phase 2 | 82 | Tongji HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05791409 | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL(AETHER) | recruiting | Phase 1 / Phase 2 | 112 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Apr 12, 2024 | clinicaltrials |
| NCT06051240 | Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy(LiBRA) | recruiting | Phase 2 | 84 | Region StockholmOTHER_GOV | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06111274 | A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 82 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06354231 | DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06354218 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06223711 | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | recruiting | Phase 2 | 43 | Universität des SaarlandesOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT05984810 | NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101(FLUOPANC-II) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06250959 | RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.(BEAT-ALL-2024) | recruiting | Phase 2 | 124 | Chen SuningOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05477264 | Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type | recruiting | Phase 2 | 38 | Won Seog KimOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05652920 | Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | recruiting | Phase 1 / Phase 2 | 105 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | recruiting | Phase 2 / Phase 3 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06345287 | Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC | recruiting | Phase 2 | 133 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06202001 | Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients | recruiting | Phase 1 / Phase 2 | 70 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341595 | Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341894 | Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer | recruiting | Phase 2 | 1,163 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
Data updated 24 days agoSource updated May 10, 2024source: clinicaltrials